Pharma Technology Focus – Issue 45

In this issue: Israel’s pharma market, what Brexit would mean for clinical research in the UK, developments in obstetrics, the trouble with inhalable insulin, the FDA’s new support for innovation in manufacturing, plant-based vaccine manufacturing and more.


Pharma Technology Focus – Issue 45

Pharma Technology Focus is free for the iPad. Download our app to read the latest issue and browse our back issues for free.

Israel's pharmaceutical and biotechnology market has a reputation for efficiency, high R&D spending and an impressive international reach, with world-class export numbers and a growing market value. We take a look at the success story behind this pharma powerhouse.

The idea of inhalable insulin has been around for some time, but with Pfizer and Sanofi dropping their pioneering products, has this form of delivery failed to live up to its promise? Also in this issue, we find out how a focus on existing treatments is improving the standard of care in obstetrics, hear from GlobalData about progress in tobacco-based flu vaccine manufacturing, and take a look at the FDA's new programme to help companies implement innovative manufacturing technologies.

Plus, we ask what Brexit would mean for clinical research and funding in the UK, and find out how behavioural science could help to change doctors' antibiotics prescription practices.

Read the issue for free on your iPad through our app, or if you're on a desktop computer you can also read it in our web viewer.

In this issue

The Wrong Exit
The EU's flawed Clinical Trials Directive has been held up as a reason why the UK's pharma sector would be better off outside of Europe. But with reform on the way and a raft of research funding and partnerships at stake, Chris Lo asks: Does this claim hold up?
Read the article.

A Growing Pharma Powerhouse
Israel's pharmaceutical market has a reputation for high R&D spending and an impressive international reach, with world-class export numbers and a growing market value. Chris Lo explores the secret behind the country's success.
Read the article.

Exploring New Possibilities
Pregnancy and childbirth still pose significant health risks for women, and while new drug approvals are thin on the ground, the industry is on the case in other ways. Elly Earls profiles recent innovations in this important field.
Read the article.

A Losing Battle?
The idea of delivering insulin via inhaler has been around for some time, but with Pfizer and Sanofi dropping their pioneering products, has this form of delivery failed to live up to its promise? Abi Millar investigates.
Read the article.

Plant Power
Mitsubishi Tanabe Pharma plans to advance the first tobacco-based, virus-like particle seasonal influenza vaccine in phase III studies. Achilleas Livieratos, PhD, GlobalData analyst for infectious diseases, discusses the company's goal of launching the vaccine in the US market by the 2018-2019 flu season.
Read the article.

Encouraging Innovation
The FDA is implementing a new programme allowing pharma companies to submit novel manufacturing technologies for expedited review. Abi Millar asks how the process will work in practice.
Read the article.

Start as You Mean to Go On
Without R&D, life sciences companies would have no new products to market. Yet it's often neglected in companies' information management plans, and that could be holding companies back in all sorts of ways, warns Elvis Pacelat, vice president of compliance solutions at AMPLEXOR Life Sciences.
Read the article.

A Nudge in the Right Direction
A study has successfully used behavioural science to change doctors' antibiotics prescribing practices. Elly Earls asks the study's senior author Dr Jason Doctor how behavioural interventions can tackle the over-prescription of antibiotics.
Read the article.

Preview: May issue

The WHO has declared the Zika virus outbreak in South and Central America a global public health emergency, citing the potential for the virus to spread rapidly and a lack of vaccines and reliable diagnostic tests. We investigate the challenges involved in tracking the spread of the virus and the prospects for a vaccine.

We also ask what lessons can be learned from Bial's BIA 10-2474 clinical trial disaster in France, explore the viability of the US's $1bn 'moonshot' effort to cure cancer, and speak to researchers investigating the manipulation of T cells as a new path to cancer treatment.

Plus, we find out why scientists are digging up Kentucky's mines in the search for micro-organisms with therapeutic potential, and take a look at the latest digital technologies being applied to pharmaceutical packaging to protect the contents from tampering and counterfeiting.

Digital magazine FAQ

You can read Pharma Technology Focus for free on the iPad. Download our app from the App Store to read the latest issue and browse the back issues in our archive. Sign up for a free subscription in the app and never miss a new issue.

You can also continue to read the desktop version for free on our web viewer. (Browser compatibility: The web viewer works in the latest two version of Chrome, Firefox and Safari, as well as in Internet Explorer 9 and 10. Some features may not be compatible with older browser versions.)